Ildong Pharmaceutical announced Monday that it has signed a contract with its Indonesian partner Kalbe Pharma to expand supply of its cholesterol treatment 'Droptop' to additional Southeast Asian markets. Droptop is a combination drug for treating dyslipidemia that combines rosuvastatin, a statin-class medication that inhibits cholesterol synthesis in the body, with ezetimibe, a compound that blocks intestinal cholesterol absorption.
Ildong Pharmaceutical has expanded the supply territory for Droptop through this contract with Kalbe International, the distribution affiliate of Kalbe Pharma. By entering three additional ASEAN countries, the company has now established a partnership with the Kalbe Group covering dyslipidemia treatment markets in a total of eight countries.
The collaboration between Ildong Pharmaceutical and Kalbe Pharma, Indonesia's top pharmaceutical company, began in 2020. After the two companies signed a partnership agreement for Droptop supply at that time, exports have continued since 2023. Droptop is sold locally under the brand name 'Rozet' and has recorded an average annual growth rate of approximately 130% over the three years since launch. According to Ildong Pharmaceutical, Droptop currently holds the No. 1 market share in Indonesia's combination drug segment for dyslipidemia treatment.
Ildong Pharmaceutical plans to sequentially pursue product registration and launch procedures in the contracted countries through its partnership with the Kalbe Group, while implementing localized marketing and distribution strategies. "We will continue to expand our market reach and product lineup together with the Kalbe Group," an Ildong Pharmaceutical official said.
